Vigil Neuroscience, Inc. VIGL 深 滬
已收盤 09-19 16:00:00 美东时间
3.43
-0.040
-1.15%
華盛通- 最 高3.6373
- 今 開3.58
- 成交量 11.27万股
- 最 低 3.4263
- 昨 收 3.47
- 總市值 1.23亿
- 52周最高 9.24
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 2.47
- 委 比 70.17%
- 總股本 3587.34万
- 歷史最高 18.27
- 量 比 1.35
- 振 幅 6.08%
- 歷史最低 2.18
- 每 手 1
- 風險率 1.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vigil says FDA removed partial hold on Alzheimer’s candidate
Vigil Neuroscience (NASDAQ:VIGL) announced Tuesday that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial for its Alzheimer’s cand...
09-17 20:19
Vigil Neuroscience GAAP EPS of -$0.52
Vigil Neuroscience press release (NASDAQ:VIGL): Q2 GAAP EPS of -$0.52. Cash, cash equivalents, and marketable securities were $86.7 million as of June 30, 2024, compared to $101.6 million as of March ...
08-13 20:35
快讯 | Vigil Neuroscience Inc宣布赛诺菲安万特投资了4000万美元；现金流至2026年延长。
Vigil Neuroscience Inc: Announced $40 Mln Strategic Investment From Sanofi; Ext...
08-13 19:07
快讯 | Vigil Neuroscience Q2每股收益为-0.52美元，IBES估计为-0.55美元。
Vigil Neuroscience Q2 EPS USD -0.52 Vs. IBES Estimate USD -0.55
08-13 19:00
快讯 | Vigil神经科学第二季度营业收入为美元指数-2247.8万，IBES估值为美元指数-2260万
Vigil Neuroscience Q2 Operating Income USD -22.478 Million Vs. IBES Estimate US...
08-13 19:00
快讯 | Vigil Neuroscience第二季度营业费用为2247.8美元指数
Vigil Neuroscience Q2 Operating Expenses USD 22.478 Million
08-13 19:00
快讯 | 祈福神经科学报告2024年第二季度财务结果并提供业务更新
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides B...
08-13 19:00
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
Vigil Neuroscience Inc. (NASDAQ:VIGL) released interim data on Wednesday from i...
07-25 03:12
Vigil Neuroscience’s Promising Phase 1 Trial and Alzheimer’s Focus
Vigil Neuroscience Inc (VIGL) has issued an update. Vigil Neuroscience, Inc. re...
07-24 19:48
快讯 | 警惕神经科学公司公布了其正在进行的Vg-3927健康志愿者阶段1临床试验的中期数据，该数据支持继续发展用于阿尔茨海默病的药物。
Vigil Neuroscience Announces Interim Data From Its Ongoing Phase 1 Clinical Tri...
07-24 19:00
